Wisevoter
U.S.

HexemBio Secured $15.5 Million in Funding

The biotech firm raised capital to advance its research into aged blood stem cell regeneration technology.

Updated on Sept. 22, 2026 in Biotech

Bold flat-color editorial illustration featuring a symbolic glass bioreactor with floating geometric cell structures, representing biomedical stem cell research.
Biotech startup HexemBio secured $15.5 million in a funding round led by Draper Associates to advance blood stem cell regeneration therapies. AI Illustration. Upload story photo >

Live Poll

Are you optimistic that new regenerative medical technologies will effectively treat age-related diseases?

HexemBio has raised $15.5 million in a new funding round led by Draper Associates. The investment included $2 million from Korean Investment Partners to support the development of therapies for aged blood stem cell regeneration.

Why it matters

The company aims to restore function to hematopoietic stem cells through a synthetic human yolk sac environment rather than genetic reprogramming. This approach offers a novel strategy for treating age-related blood conditions.

HexemBio has filed 17 patent cases with the USPTO, with two patents currently registered. The company technology exposes extracted stem cells to a synthetic human yolk sac environment.

The players

HexemBio

This biotechnology company focuses on developing therapies to regenerate aged blood stem cells.

Korean Investment Partners

This firm is a venture capital investor that contributed $2 million to the recent funding round.

Draper Associates

This venture capital firm led the recent $15.5 million funding round for the company.

Food and Drug Administration

This U.S. federal agency regulates pharmaceutical drug development and granted Orphan Drug Designation to the company.

The details

HexemBio focuses on regenerating aged blood stem cells using a synthetic human yolk sac environment. The firm has already secured FDA Orphan Drug Designation and completed a pre-IND meeting to prepare for future clinical applications.

Timeline

  1. July 2025: HexemBio received FDA Orphan Drug Designation.

  2. January 2026: The company completed a pre-IND meeting with the FDA.

  3. September 22, 2026: Korean Investment Partners announced their $2 million investment.

  4. 2027: HexemBio plans to initiate first-in-human dosing.

The Tech Race

The transition toward non-reprogramming-based stem cell therapies represents a shift away from traditional gene-editing technologies that often carry long-term safety risks. HexemBio is positioning itself to compete with firms using the FDA pre-IND meeting process to validate alternative regeneration methods.

The funding accelerates the timeline for bringing potentially life-saving blood therapies to market for patients with age-related conditions. If successful, this technology could provide new treatment options that bypass the risks associated with current genetic engineering procedures.

The takeaway

The successful funding round signals strong investor confidence in the move toward non-genetic regeneration techniques. Patients and stakeholders should monitor the planned 2027 clinical trials as the next milestone for this medical innovation.

What happens next

HexemBio is scheduled to conduct its first-in-human dosing in 2027.

Further reading

For more on the current trajectory of the industry, visit Biotech.

Source note: This article includes information reported by 조선일보.

Live Poll

Are you optimistic that new regenerative medical technologies will effectively treat age-related diseases?